J. Harry and . Buncke, Université d'Helsinki (FINLANDE) Professeur Paul MICHIELSEN (1979) Université Catholique, Canada) Professeur James STEICHEN, 1989.

P. Charles and A. Berry, Université de Dundee (Royaume Uni) Professeur Duong Quang TRUNG (1997) Centre Universitaire de Formation et de Perfectionnement des, 1982.

P. Marc and L. , Institute of Technology, Atlanta (USA) Professeur Mamish Nisbet MUNRO (1982) Massachusetts Institute of Technology, 2005.

R. Bibliographiques-1 and G. A. Rock, Management of thrombotic thrombocytopenic purpura, Br J Haematol, vol.109, issue.3, pp.496-507, 2000.

J. E. Sadler, Recent Advances in Thrombotic Thrombocytopenic Purpura, Hematology, vol.2004, issue.1, pp.407-430, 2004.
DOI : 10.1182/asheducation-2004.1.407

B. Lammle, J. A. Hovinga, and L. Alberio, Thrombotic thrombocytopenic purpura, J Thromb Haemost, issue.38, pp.1663-75, 2005.

J. L. Moake, Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura, N Engl J Med, issue.23, pp.307-1432, 1982.

H. M. Tsai, A. Li, and G. Rock, Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura, Clin Lab, pp.47-54, 2001.

M. Furlan, Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura, Expert Review of Cardiovascular Therapy, vol.113, issue.2, pp.243-55, 2003.
DOI : 10.1212/WNL.49.6.1552

H. M. Tsai, Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura, Journal of Thrombosis and Haemostasis, vol.63, issue.9
DOI : 10.1182/blood-2002-12-3796

J. D. Studt, Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience, Swiss Med Wkly, vol.133, pp.23-24, 2001.

F. Scheiflinger, Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura, Blood, vol.102, issue.9, pp.3241-3244, 2003.
DOI : 10.1182/blood-2003-05-1616

S. L. Allford, Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias, British Journal of Haematology, vol.120, issue.4, pp.556-73, 2003.
DOI : 10.1172/JCI112394

J. N. George, Clinical practice Thrombotic thrombocytopenic purpura, N Engl J Med, issue.18, pp.354-1927, 2006.

D. Caramazza, Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome, Blood Transfus, vol.8, issue.3, pp.203-213, 2010.

C. L. Balduini, High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study, Annals of Hematology, vol.93, issue.6, pp.591-597, 2010.
DOI : 10.1007/s00277-009-0877-5

URL : https://hal.archives-ouvertes.fr/hal-00494349

L. A. Gutterman and T. D. Stevenson, Treatment of Thrombotic Thrombocytopenic Purpura With Vincristine, JAMA: The Journal of the American Medical Association, vol.247, issue.10, pp.1433-1439, 1982.
DOI : 10.1001/jama.1982.03320350037025

L. Nguyen, Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, Transfusion, vol.48, issue.2, pp.349-57, 1989.

R. P. Bernard, A. W. Bauman, and S. I. Schwartz, Splenectomy for Thrombotic Thrombocytopenic Purpura, Annals of Surgery, vol.169, issue.4, pp.616-640, 1969.
DOI : 10.1097/00000658-196904000-00020

D. S. Allan, M. J. Kovacs, and W. F. Clark, Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy, Haematologica, issue.8, pp.86-844, 2001.

J. E. Sadler, Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura, Blood, vol.112, issue.1, pp.11-19, 2008.
DOI : 10.1182/blood-2008-02-078170

P. N. Lara and . Jr, Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, The American Journal of Medicine, vol.107, issue.6, pp.573-582, 1999.
DOI : 10.1016/S0002-9343(99)00286-7

B. Obert, Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF, Thromb Haemost, vol.82, issue.5, pp.1382-1387, 1999.

P. Bota and D. , The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction, Intensive Care Med, issue.11, pp.28-1619, 2002.

B. M. Hawkins, Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review, Transfusion, vol.139, issue.0, pp.382-92, 2008.
DOI : 10.1046/j.1526-0968.2002.00363.x

A. Druschky, Central Nervous System Involvement in Thrombotic Thrombocytopenic Purpura, European Neurology, vol.40, issue.4, pp.220-224, 1998.
DOI : 10.1159/000007983

K. Gandhi, Cardiovascular Manifestations in Patients With Thrombotic Thrombocytopenic Purpura: A Single-center Experience, Clinical Cardiology, vol.150, issue.4, pp.213-219, 2010.
DOI : 10.7326/0003-4819-65-1-37

P. Coppo, Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura, British Journal of Haematology, vol.138, issue.1, pp.66-74, 2006.
DOI : 10.1182/blood-2003-11-4035

URL : https://hal.archives-ouvertes.fr/hal-00453285

M. Darmon, Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange*, Critical Care Medicine, vol.34, issue.8, pp.34-2127, 2006.
DOI : 10.1097/01.CCM.0000227659.14644.3E

A. Veyradier, Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases, Blood, vol.98, issue.6, pp.98-1765, 2001.
DOI : 10.1182/blood.V98.6.1765

D. Caramazza, Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab, Transfusion, vol.12, issue.12, pp.50-2753, 2010.
DOI : 10.1024/0040-5930.65.12.710